Keyphrases
Type 2 Diabetes Mellitus (T2DM)
100%
Denmark
88%
COVID-19
71%
Type 2 Diabetic Patients
70%
Healthcare Workers
39%
Placebo
39%
Vital Signs
38%
Glucagon-like
37%
Glucose-dependent Insulinotropic Polypeptide
36%
Prospective Cohort Study
35%
Randomized Controlled Trial
33%
Continuous Monitoring
31%
Glucagon
31%
Acute Exacerbation of COPD (AECOPD)
31%
Emergency Department
29%
Confidence Interval
28%
A1 Receptor
28%
Polypharmacy
27%
Psoriatic Arthritis
27%
Serious Adverse Events
26%
Randomized Clinical Trial
24%
National Cohort Study
24%
Parkinson's Disease
23%
Obesity
23%
Hospitalization
22%
Randomized Placebo-controlled Trial
22%
Gene Expression
22%
Hyperoxia
21%
Hypoglycemia
21%
Medication Review
21%
Alpha-synuclein (α-syn)
21%
Readmission Risk
20%
Prospective Observational Study
20%
Hospitalized Patients
20%
Health-related Quality of Life
20%
Noncardiac Surgery
20%
Adjusted Hazard Ratio
20%
30-day Mortality
20%
Severe Mental Illness
19%
Emergency Patients
19%
Myocardial Injury
19%
Glucose-lowering Drugs
18%
Cognitive Impairment
18%
Capital Region
18%
Older Patients
17%
Placebo-controlled
17%
Copenhagen
16%
SpO2
16%
Multiple System Atrophy
16%
Arthritis Patients
16%
Clinical Outcomes
16%
Randomized Double-blind
15%
Antioxidant
15%
COVID-19 Pandemic
15%
Medical Patients
15%
Hemoglobin A1c (HbA1c)
15%
IL-17 Inhibitors
15%
Single Center
15%
Comorbidity
15%
Receptor Agonist
15%
Older Adults
14%
2 Receptor
14%
Patients with COVID-19
14%
TNF Inhibitors
14%
Readmission
14%
Diabetes
14%
Cardiovascular Risk
14%
Randomized Trial
14%
Registry-based
13%
Type I Diabetes
13%
Type 1 Diabetes Mellitus (T1DM)
13%
Muscle Strength
13%
Vaccination
13%
Discharge Diagnosis
13%
Mannose-binding Lectin
13%
Non-specific Protection
13%
Structured Summaries
13%
Sepsis
13%
Antidiabetic Drugs
13%
Medication Changes
13%
SARS-CoV-2 Detection
13%
Sensorimotor Gating
13%
Health Protection
13%
Rapid Detection
13%
Geriatric Outpatients
13%
Observational Cohort Study
13%
Wireless
13%
Glycocalyx
13%
Cognitive Performance
13%
Nested Case-control Study
13%
Non-responders
13%
Hazard Ratio
13%
T Helper 17 (Th17)
12%
Alzheimer's Disease
12%
Synucleinopathy
12%
Patients with Diabetes
12%
Hyperglycemia
12%
Sulfonylurea
11%
Limits of Agreement
11%
Receptor-binding Domain
11%
Medicine and Dentistry
Drug Therapy
66%
Maturity Onset Diabetes of the Young
64%
Cohort Analysis
56%
Placebo
52%
Patient with Type 2 Diabetes
44%
COVID-19
41%
Emergency Department
40%
Observational Study
39%
Vital Sign
39%
Gastric Inhibitory Polypeptide
33%
Infection
30%
Adverse Event
29%
Diabetes
29%
Randomized Clinical Trial
28%
Prospective Cohort Study
28%
Hazard Ratio
27%
Infusion
23%
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
21%
Heart Muscle Injury
21%
Hypoglycemia
20%
Noncardiac Surgery
20%
Disease
20%
Polypharmacy
19%
Antioxidant
19%
Severe Mental Illness
19%
Randomized Controlled Trial
19%
Severe Acute Respiratory Syndrome Coronavirus 2
19%
Symptom
18%
Quality of Life
18%
Antidiabetic Agent
17%
Receptor
16%
Cardiovascular System
15%
Chronic Obstructive Pulmonary Disease
15%
Glucagon Like Peptide 1 Receptor
14%
Health Care
14%
Hyperoxia
14%
Medicine
14%
Food Intake
13%
Outpatient
13%
Malignant Neoplasm
13%
Case-Control Study
13%
Sepsis
13%
Muscle Strength
12%
Insulin Dependent Diabetes Mellitus
12%
Glucagon-Like Peptide-1 Agonist
11%
Hyperglycemia
11%
Patient with Diabetes
11%
Sulfonylurea
11%
Glucagon Like Peptide 1
11%
Body Mass Index
11%
Heart Failure
10%
Clinical Trial
10%
Dipeptidyl Peptidase-4 Inhibitor
10%
Body Weight
10%
Glycon
10%
SOFA Score
10%
Glucagon
10%
Glycemic Control
9%
Systemic Inflammatory Response Syndrome
9%
Sarcopenia
9%
Geriatrics
9%
Oxygen Saturation
9%
Biological Marker
9%
Proportional Hazards Model
9%
Dyspnea
9%
Resistance Training
8%
Obesity
8%
Frailty
8%
Quantitative Reverse Transcription Polymerase Chain Reaction
8%
Gastrointestinal Cancer
8%
Patient with Type 1 Diabetes
7%
Glycemic
7%
Cross Sectional Study
7%
Anodyne
7%
Parkinson's Disease
7%
Major Surgery
7%
Computer Assisted Tomography
6%
Mannose Binding Lectin
6%
Renin-Angiotensin System Inhibitor
6%
Hip
6%
Electrocardiography Monitoring
6%
Cognition
6%
Knee Osteoarthritis
6%
Symptomatic Treatment
6%
Influenza Vaccination
6%
Articular Cartilage
6%
Systematic Review with Meta-Analysis
6%
Atrial Fibrillation
6%
Psychoactive Drug
6%
Shy-Drager Syndrome
6%
Total Knee Arthroplasty
6%
Sodium Glucose Cotransporter
6%
Lymph Duct
6%
Surgery
6%
Diet Therapy
6%
Gene Expression
6%
Controlled Clinical Trial
6%
Cytokine
6%
Tumor Necrosis Factor
6%
Homeostasis
6%